Lanean...
Phase I safety study of ranolazine in pulmonary arterial hypertension
Abstract. Pulmonary arterial hypertension (PAH) causes right ventricular ischemia, dysfunction, and failure. PAH patients may benefit from antianginal agents based on a shared pathophysiology with left ventricular ischemia. A single-center, randomized, placebo-controlled trial (1∶1) to assess the ac...
Gorde:
| Argitaratua izan da: | Pulm Circ |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
University of Chicago Press
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4671743/ https://ncbi.nlm.nih.gov/pubmed/26697176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/683813 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|